The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
Open accessAbstract
Aberrant activation of Bruton’s tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies. The discovery of a more selective on-target covalent BTK inhibitor is of high value. Herein, we disclose the discovery and preclinical characterization of a potent, selective, and irreversible BTK inhibitor as our clinical candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compounds. Compound BGB-3111 ( 31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Towards automated crystallographic structure refinement with phenix.refine
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Vetrie, D., Vořechovský, I., Sideras, P., Holland, J., Davies, A., Flinter, F., Hammarström, L., Kinnon, C., Levinsky, R., Bobrow, M., et al. (1993) · Nature · doi:10.1038/361226a0 · Cited by 1,461
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Pan, Z., Scheerens, H., Li, S., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C. K., Grothaus, P. G., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200600221 · Cited by 674
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
Self-citationBauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Primary B Cell Immunodeficiencies: Comparisons and Contrasts
Conley, M. E., Dobbs, A. K., Farmer, D. M., Kilic, S., Paris, K., Grigoriadou, S., Coustan-Smith, E., Howard, V., & Campana, D. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132649 · Cited by 426
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A. D., Darrow, J., Davies, D. R., DeForge, L. E., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.481 · Cited by 340
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
Smith, C. I. E., Baskin, B., Humire-Greiff, P., Zhou, J. N., Olsson, P. G., Maniar, H. S., Kjellén, P., Lambris, J. D., Christensson, B., Hammarström, L., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.2.557 · Cited by 305
Src family kinases: at the forefront of platelet activation
Senis, Y. A., Mazharian, A., & Mori, J. (2014) · Blood · doi:10.1182/blood-2014-01-453134 · Cited by 296
Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 268
Skin toxicities associated with epidermal growth factor receptor inhibitors
Li, T., & Perez-Soler, R. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0114-0 · Cited by 261
The Src, Syk, and Tec family kinases: Distinct types of molecular switches
Bradshaw, J. M. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.03.001 · Cited by 256
Evans, E. K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M. T., Witowski, S. R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203489 · Cited by 220
The road map to oral bioavailability: an industrial perspective
Thomas, V. H., Bhattachar, S., Hitchingham, L., Zocharski, P., Naath, M., Surendran, N., Stoner, C. L., & El-Kattan, A. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.4.591 · Cited by 168
Marcotte, D. J., Liu, Y., Arduini, R. M., Hession, C. A., Miatkowski, K., Wildes, C. P., Cullen, P. F., Hong, V. S., Hopkins, B. T., Mertsching, E., et al. (2010) · Protein Science · doi:10.1002/pro.321 · Cited by 158
Self-citationScheers, E. M., Leclercq, L., de Jong, J., Bode, N., Bockx, M., Laenen, A., Cuyckens, F., Skee, D. M., Murphy, J., Sukbuntherng, J., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060061 · Cited by 148
Bye, A. P., Unsworth, A. J., Desborough, M., Hildyard, C., Appleby, N., Bruce, D., Kriek, N., Nock, S. H., Sage, T., Hughes, C. E., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017011999 · Cited by 134
Saffran, D. C., Parolini, O., Fitch-Hilgenberg, M. E., Rawlings, D. J., Afar, D., Witte, O. N., & Conley, M. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405263302104 · Cited by 129
Watterson, S. H., Liu, Q., Bertrand, M. B., Batt, D. G., Li, L., Pattoli, M. A., Skala, S., Cheng, L., Obermeier, M. T., Moore, R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00167 · Cited by 120
Humphries, L. A., Dangelmaier, C., Sommer, K., Kipp, K. R., Kato, R. M., Griffith, N., Bakman, I., Turk, C. W., Daniel, J. L., & Rawlings, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311985200 · Cited by 104
Arnold, L. D., Calderwood, D. J., Dixon, R. W., Johnston, D. N., Kamens, J., Munschauer, R., Rafferty, P., & Ratnofsky, S. E. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00441-8 · Cited by 97
Crystal Structures of Active Src Kinase Domain Complexes
Breitenlechner, C. B., Kairies, N., Honold, K., Scheiblich, S., Koll, H., Greiter, E., Koch, S., Schäfer, W., Huber, R., & Engh, R. A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.08.023 · Cited by 76
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Kaur, V., & Swami, A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2973-2 · Cited by 75
de Vries, R., Smit, J. W., Hellemans, P., Jiao, J. J., Murphy, J., Skee, D. M., Snoeys, J., Sukbuntherng, J., Vliegen, M., Zwart, L. D., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12787 · Cited by 74
Chen, J., Kinoshita, T., Gururaja, T. L., Sukbuntherng, J., James, D. F., Lu, D., Whang, J. A., Versele, M., & Chang, B. Y. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13148 · Cited by 46
Jansma, A., Zhang, Q., Li, B., Ding, Q., Uno, T., Bursulaya, B. D., Liu, Y., Furet, P., Gray, N. S., & Geierstanger, B. H. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm700983a · Cited by 39
Self-citationSupportive Care Treatments for Toxicities of Anti-EGFR and Other Targeted Agents
Melosky, B. L. (2012) · Current Oncology · doi:10.3747/co.19.1054 · Cited by 38
Tam, C. S. L., Opat, S., Cull, G., Trotman, J., Gottlieb, D. J., Simpson, D., Marlton, P. V., Anderson, M. A., Ku, M., Ritchie, D., et al. (2016) · Blood · doi:10.1182/blood.v128.22.642.642 · Cited by 37
Self-citationKersseboom, R., Kil, L. P., Flierman, R., van der Zee, M., Dingjan, G. M., Middendorp, S., Maas, A., & Hendriks, R. W. (2010) · European Journal of Immunology · doi:10.1002/eji.201040521 · Cited by 33
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E. M., Govender, T., Naicker, T., & Kruger, H. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113705 · Cited by 625
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211582 · Cited by 489
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
Kumar, A., Singh, A. K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J. P., Pathak, P., Grishina, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020299 · Cited by 363
Metadata
- Authors
- Guo, Y., Liu, Y., Hu, N., Yu, D., Zhou, C., Shi, G., Zhang, B., Wei, M., Liu, J., Luo, L., Tang, Z., Song, H., Guo, Y., Liu, X., Su, D., Zhang, S., Song, X., Zhou, X., Hong, Y., Chen, S., Cheng, Z., Young, S., Wei, Q., Wang, H., Wang, Q., Lv, L., Wang, F., Xu, H., Sun, H., Xing, H., Li, N., Zhang, W., Wang, Z., Liu, G., Sun, Z., Zhou, D., Li, W., Liu, L., Wang, L., & Wang, Z.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-08-05
- Volume
- 62
- Issue
- 17
- Pages
- 7923-7940
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2972482801
- Cited by
- 359
- References
- 39
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.